FDA sets January decision for Pharming Group’s lower-dose Joenja pediatric expansion
FDA grants Priority Review to lower-dose Joenja for children with APDS weighing 13–27 kg, setting a January 30, 2027 decision date.
Pharma & Biotech
Pharma & Biotech
How Pharming’s Joenja resubmission could reopen the FDA pathway for pediatric APDS treatment
Find out how Pharming’s Joenja sNDA resubmission could reopen the FDA pathway for younger children with APDS.